Uludag O, Cinar S, McDonnell T, Cene E, Yalcinkaya Y, Gul A
Turk J Med Sci. 2024; 53(5):1067-1074.
PMID: 38813003
PMC: 10763812.
DOI: 10.55730/1300-0144.5671.
Cheldieva F, Reshetnyak T, Shumilova A, Nurbaeva K, Cherkasova M, Lila A
Dokl Biochem Biophys. 2023; 511(1):227-234.
PMID: 37833610
PMC: 10739503.
DOI: 10.1134/S160767292370028X.
Alijotas-Reig J, Esteve-Valverde E, Anunciacion-Llunell A, Marques-Soares J, Pardos-Gea J, Miro-Mur F
J Clin Med. 2022; 11(3).
PMID: 35160128
PMC: 8836886.
DOI: 10.3390/jcm11030675.
Uludag O, Bektas M, Cene E, Sezer M, Sahinkaya Y, Gul A
J Thromb Thrombolysis. 2020; 51(2):466-474.
PMID: 32588289
DOI: 10.1007/s11239-020-02195-4.
Petri M
Hematology Am Soc Hematol Educ Program. 2019; 2019(1):415-420.
PMID: 31808834
PMC: 6913440.
DOI: 10.1182/hematology.2019000046.
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.
Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou M, Ugarte A
Semin Arthritis Rheum. 2019; 49(3):464-468.
PMID: 31153708
PMC: 7402528.
DOI: 10.1016/j.semarthrit.2019.04.009.
Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.
Zigon P, Podovsovnik A, Ambrozic A, Tomsic M, Hocevar A, Gaspersic N
Clin Rheumatol. 2018; 38(2):371-378.
PMID: 30099654
DOI: 10.1007/s10067-018-4251-7.
Diagnosis and management of the antiphospholipid syndrome.
Chaturvedi S, McCrae K
Blood Rev. 2017; 31(6):406-417.
PMID: 28784423
PMC: 5714279.
DOI: 10.1016/j.blre.2017.07.006.
Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.
Sciascia S, Amigo M, Roccatello D, Khamashta M
Nat Rev Rheumatol. 2017; 13(9):548-560.
PMID: 28769114
DOI: 10.1038/nrrheum.2017.124.
How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores.
Oku K, Amengual O, Yasuda S, Atsumi T
Curr Rheumatol Rep. 2017; 19(8):51.
PMID: 28741233
DOI: 10.1007/s11926-017-0674-4.
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.
Chaturvedi S, McCrae K
Curr Rheumatol Rep. 2017; 19(7):43.
PMID: 28711993
DOI: 10.1007/s11926-017-0668-2.
Recent advances in understanding antiphospholipid syndrome.
Bertolaccini M, Sanna G
F1000Res. 2017; 5:2908.
PMID: 28105326
PMC: 5224683.
DOI: 10.12688/f1000research.9717.1.
Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay.
Sciascia S, Baldovino S, Schreiber K, Solfietti L, Radin M, Cuadrado M
Clin Mol Allergy. 2016; 14:6.
PMID: 27429595
PMC: 4947367.
DOI: 10.1186/s12948-016-0043-2.
